FibroGen (FGEN) – Major News
-
FibroGen (FGEN) Tops Q3 EPS by 3c
-
FibroGen (FGEN) Misses Q2 EPS by 20c
-
FibroGen (FGEN) to cut 32% of U.S workforce
-
FibroGen (FGEN) Misses Q1 EPS by 6c
-
FibroGen (FGEN) Tops Q4 EPS by 21c
-
FibroGen (FGEN) Tops Q2 EPS by 14c
-
FibroGen (FGEN) Misses Q4 EPS by 79c
-
FibroGen (FGEN) Tops Q3 EPS by 55c; Reports Cash and Cash Equivalents of $665.0M
-
FibroGen (FGEN) Misses Q2 EPS by 100c
-
FibroGen (FGEN) Says FDA Advisory Committee Voted to Recommend Not Approving Roxadustat
-
FibroGen (FGEN) Tops Q1 EPS by 9c, Revenues Miss
-
FibroGen (FGEN) Misses Q4 EPS by 53c, Revenues Miss
-
FibroGen (FGEN) Misses Q3 EPS by 2c, Revenues Miss
-
FibroGen (FGEN) Posts Large Q2 EPS, Rev Beat
-
FibroGen (FGEN) Reports Q1 Loss of $0.53/Share
-
FibroGen (FGEN) Tops Q4 EPS by 30c
-
FibroGen (FGEN) Misses Q3 EPS by 15c
-
FibroGen (FGEN) Tops Q2 EPS by 31c
-
FibroGen (FGEN) Tops Q1 EPS by 1c
-
FibroGen (FGEN) Tops Q4 EPS by 2c
-
FibroGen (FGEN) Surges 47% as Phase 2 Study of Pamrevlumab in IPF Meets Primary Endpoint
-
FibroGen (FGEN) Tops Q3 EPS by 21c
-
FibroGen (FGEN) Tops Q1 EPS by 11c
-
FibroGen (FGEN) Tops Q2 EPS by 10c
-
FibroGen (FGEN) Misses Q1 EPS by 26c
-
FibroGen (FGEN) IPO Opens Above Initial Pricing at $23/Share
Back to FGEN Stock Lookup